Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07584720

Study of Midomafetamine in Healthy Adults

This Phase 1 study is designed to evaluate the safety and tolerability of midomafetamine in healthy adult participants. The study will also assess how the drug is processed in the body and characterize its effects following administration at two dose levels, including evaluation of cardiac safety using electrocardiographic assessments.

This is a single-center, open-label study in which participants will be enrolled into one of two cohorts receiving either a therapeutic dose or a supratherapeutic dose of midomafetamine. Participants will receive study drug in a split dose administration (an initial dose followed by an additional dose 1.5 hours later) and will undergo clinical assessments, laboratory testing, electrocardiographic monitoring, and monitoring for adverse events.

Information collected from this study will be used to support the ongoing clinical development of midomafetamine.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Healthy Volunteers

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Dr. Vince Clinical Research

Overland Park, Kansas, 66212, United States

About this study

This Phase 1 study is a dedicated safety investigation conducted in healthy adult participants to further characterize the safety and tolerability of midomafetamine under controlled dosing conditions. Participants will receive a split dose administration of midomafetamine (an initial dose of study drug followed by an additional dose 1.5 hours later) in sequential dose cohorts intended to achieve therapeutic and supratherapeutic systemic exposure.

Safety assessments include monitoring of adverse events, clinical laboratory tests, vital signs, and electrocardiographic measurements. Electrocardiographic data, including assessment of corrected QT interval, will be collected to support evaluation of cardiac safety in relation to exposure.

Because midomafetamine produces acute psychoactive effects during the dosing period, pharmacodynamic assessments-including subjective effects-will be collected to support interpretation of safety and tolerability findings. Pharmacokinetic assessments will also be performed to characterize systemic exposure.

This study is not designed to evaluate efficacy or treatment effectiveness for any disease or condition. Information collected from this study will be used to support the ongoing clinical development of midomafetamine.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adult participants, 18 to 55 years of age
  • Medically healthy as determined by medical history, physical examination, clinical laboratory testing, vital signs, and electrocardiogram
  • Able and willing to comply with study procedures

Exclusion criteria

  • History of clinically significant cardiovascular, neurological, or psychiatric disease
  • Current or recent substance use disorder, or positive drug or alcohol screen at screening
  • Prior exposure to midomafetamine exceeding a protocol-defined limit intended to minimize confounding of safety assessments (no more than 10% of participants may have lifetime prior exposure)
  • Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with interpretation of study results

Treatment and study plan

Midomafetamine HCl

Drug

Midomafetamine HCl is administered orally to study participants.

Other names: Midomafetamine

Primary outcomes

  1. Incidence of Adverse Events

    Time frame: From signing of informed consent through End of Study visit (Day 30 +/- 2 Days)

    Assessment of adverse events and serious adverse events following administration of midomafetamine.

Secondary outcomes

  1. Change from baseline in corrected QT interval (QTc) (ms)

    Time frame: Baseline (predose Day 1) and up to 24 hours postdose (Day 2)

    Corrected QT interval (QTc) will be assessed using 12-lead ECG data and summarized as change from baseline at multiple postdose timepoints through 24 hours after dosing.

  2. Maximum plasma concentration (Cmax) of midomafetamine

    Time frame: Predose (Day 1) through 48 hours postdose (Day 3)

    Plasma midomafetamine concentrations will be measured, and maximum plasma concentration (Cmax) will be derived from the concentration-time data.

  3. Time to maximum plasma concentration (Tmax) of midomafetamine

    Time frame: Predose (Day 1) through 48 hours postdose (Day 3)

    Plasma midomafetamine concentrations will be measured, and time to maximum plasma concentration (Tmax) will be derived from the concentration-time data.

  4. Area under the plasma concentration-time curve (AUC0-24) of midomafetamine

    Time frame: Predose (Day 1) through 24 hours postdose (Day 2)

    Plasma midomafetamine concentrations will be measured, and area under the concentration-time curve from time 0 to 24 hours (AUC0-24) will be derived from the concentration-time data.

  5. Change from baseline in subjective effects Visual Analog Scale (VAS) scores

    Time frame: Baseline (predose Day 1) and up to 24 hours postdose (Day 2)

    Subjective effects will be assessed using Visual Analog Scale (VAS) instruments and summarized as change from baseline at multiple postdose timepoints through 24 hours after dosing.

Sponsors and collaborators

Lead sponsor

Resilient Pharmaceuticals

Industry

Collaborators

  • Dr. Vince Clinical Research

Registry information

Official study title

A Phase 1, Single-Center, Open-Label, 2-Cohort Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Midomafetamine at Therapeutic and Supratherapeutic Doses

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
May 13, 2026
Registry last updated
Jun 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.